B7H3 CAR-T dnTGFBRII

B7H3 CAR-T dnTGFBRII is an investigational autologous chimeric antigen receptor T cell (CAR‑T) therapy engineered to target the immune checkpoint molecule B7‑H3 (CD276) on tumor cells while co-expressing a dominant‑negative transforming growth factor beta receptor II (dnTGFBRII) to resist TGF‑β–mediated immunosuppression in the tumor microenvironment. B7‑H3 is a type I transmembrane protein of the B7 family that is overexpressed on a wide range of pediatric and adult solid tumors, including brain tumors, and has limited expression in normal tissues, making it an attractive immunotherapy target.[2][3][5] The dnTGFBRII component is a truncated TGF‑β receptor that lacks intracellular signaling domains, allowing the modified T cells to bind TGF‑β without propagating inhibitory SMAD signaling, thereby preserving their cytolytic function, activation, and persistence in TGF‑β–rich tumors as shown for analogous B7H3 CAR immune cell products.[2] This product is being developed as a novel immuno‑oncology cell therapy for relapsed or refractory solid tumors, particularly central nervous system and other B7‑H3–positive malignancies, and remains at an early, preclinical or first‑in‑human development stage.